C. Ciunci

发表

Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy.

S. Feigenberg, W. Hwang, A. Berman, 2020, Clinical lung cancer.

Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non–Small-Cell Lung Cancer Harboring MET Exon 14 Skipping

J. Heymach, P. Paik, A. Tsao, 2021, JCO Precision Oncology.

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer

Sharyn I. Katz, K. Elenitoba-Johnson, W. Hwang, 2019, JAMA oncology.

Trends in surveillance for resected colorectal cancer, 2001‐2009

A. Vachani, A. Epstein, Christine M. Veenstra, 2015, Cancer.

Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial.

C. Langer, R. Mick, R. Cohen, 2019, JAMA oncology.

Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.

C. Langer, R. Mick, R. Cohen, 2022, Clinical lung cancer.

Special topics in immunotherapy and radiation therapy: reirradiation and palliation.

D. Gomez, T. Evans, C. Ciunci, 2007, Translational lung cancer research.

Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy

Sharyn I. Katz, C. Langer, S. Yee, 2021, JCO precision oncology.

A single-center retrospective cohort study of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma

Sharyn I. Katz, K. Cengel, C. Langer, 2022, PloS one.

Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC—Results From a Prospective Pilot Study

A. Lanfranco, Kevin C. Ma, W. Hwang, 2022, JTO clinical and research reports.

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.

C. Langer, A. Vachani, R. Cohen, 2017, Lung cancer.

Case Report of Acute Splenic Sequestration Crisis in an Adult Patient with Hb S Disease and Suspected Hereditary Persistence of Fetal Hemoglobin

Ian R. Sigal, C. Ciunci, 2021, Hemoglobin.

Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.

E. Genden, T. Fojo, S. Bates, 2018, Journal of the National Cancer Institute.

Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer

E. Helman, W. Hwang, A. Berman, 2020, Clinical Cancer Research.

Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.

C. Langer, R. Mick, E. Carpenter, 2018, JCO precision oncology.

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Anil Vachani, Charu Aggarwal, Andrea B. Troxel, 2016, Clinical Cancer Research.

Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non-Small-Cell Lung Cancer.

W. Hwang, C. Langer, J. Rosenbaum, 2019, JCO precision oncology.

Management of Lung Cancer During the COVID-19 Pandemic.

S. Feigenberg, L. Shulman, A. Berman, 2020, JCO oncology practice.

Early Tumor and Nodal Response in Patients with Locally Advanced Non-Small Cell Lung Carcinoma Predict for Oncologic Outcomes in Patients Treated with Concurrent Proton Therapy and Chemotherapy

Eun Jeong Min, K. Cengel, S. Feigenberg, 2020 .

Multi‐Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non–Small Cell Lung Cancer

C. Simone, S. Hahn, A. Berman, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer

K. Flaherty, H. Kang, A. Troxel, 2014, Cancer.

P3.02c-028 Outcomes of Nivolumab in Elderly Patients (pts) with Non-Small Cell Lung Cancer (NSCLC): Topic: IT

C. Langer, A. Vachani, R. Cohen, 2017 .

Trends in the Use of (18)F-Fluorodeoxyglucose PET Imaging in Surveillance of Non-Small-Cell Lung and Colorectal Cancer.

A. Vachani, H. Zafar, A. Epstein, 2016, Journal of the American College of Radiology : JACR.

Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System.

K. Cengel, S. Feigenberg, A. Berman, 2023, Clinical lung cancer.

Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma.

Sharyn I. Katz, M. Zauderer, K. Cengel, 2023, JAMA network open.

Early Tumor and Nodal Response in Patients with Locally-advanced NSCLC Predict for Oncologic Outcomes in Patients Treated with Concurrent Proton Therapy and Chemotherapy: Tumor Regression Predicts Outcomes in LA-NSCLC.

Eun Jeong Min, K. Cengel, S. Feigenberg, 2019, International journal of radiation oncology, biology, physics.

Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of Immunotherapy.

W. Hwang, C. Langer, R. Cohen, 2022, Clinical lung cancer.

Trends in Use of FDG-PET Imaging in Surveillance of Non-Small Cell Lung and Colorectal Cancer

A. Vachani, A. Epstein, Christine M. Veenstra, 2019 .

A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer

C. Langer, R. Cohen, R. Amaravadi, 2023, The oncologist.

MA25.04 Blood-Based Tumor Mutation Burden as a Predictive Biomarker for Outcomes After Pembrolizumab Based First Line Therapy in Metastatic NSCLC

C. Langer, S. Yee, E. Carpenter, 2019, Journal of Thoracic Oncology.

Patterns of Failure in Metastatic NSCLC Treated with First Line Pembrolizumab and Use of Local Therapy in Patients with Oligoprogression

K. Cengel, S. Feigenberg, C. Langer, 2023, Clinical Lung Cancer.